PMDA drug package insert
リピトール錠5mg
PMDA Prescription drug · ヴィアトリス製薬合同会社 · package insert May 1, 2026
Key facts
| Brand names | リピトール錠5mg, リピトール錠10mg |
|---|---|
| Nonproprietary names | アトルバスタチンカルシウム水和物 |
| Companies | 製造販売元／ヴィアトリス製薬合同会社 |
| Product type | Prescription drug |
| Therapeutic category | HMG-CoA還元酵素阻害剤 |
| Therapeutic category codes | 872189 |
| YJ codes | 2189015F1023, 2189015F2020 |
| Approval numbers | 21200AMZ00158, 21200AMZ00159 |
| Package insert edition | 第7版 |
| Package insert date | May 1, 2026 |
| PMDA document key | 671450_2189015F1023_2 |
| PMDA company code | 671450 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: